|- candidate number||23356|
|- NTR Number||NTR5519|
|- ISRCTN||ISRCTN no longer applicable|
|- Date ISRCTN created|
|- date ISRCTN requested|
|- Date Registered NTR||4-nov-2015|
|- Secondary IDs||Eudra CT 2014-002686-30|
|- Public Title||Determinants of succesful discontinuation of antipsychotics used for behavioural symptoms in people with intellectual disability|
|- Scientific Title||Determinants of succesful discontinuation of antipsychotics used for behavioural symptoms in people with intellectual disability|
|- hypothesis||Succesful discontinuation of antipsychotics used for behavioural symptoms in people with intellectual disability is determined by staff-related factors and by neurological withdrawal symptoms.|
|- Healt Condition(s) or Problem(s) studied|
|- Inclusion criteria||• Any sex or ethnicity
• Age ≥ 6 years
• Functioning below an IQ level of 70 as assessed by an authorized behavioral scientist
• Subjects have used one or more antipsychotics for more than one year for challenging behavior
• Subjects have been presented a treatment proposal of an attempt to discontinue antipsychotics by their physician.
Written informed consent of the legal representative.
|- Exclusion criteria||A potential subject who meets any of the following criteria will be excluded from participation in this study: |
• A history of schizophrenia, a bipolar disorder, or affective psychosis according to DSM IV or ICD-10 criteria
• A history of unsuccessful withdrawal of antipsychotics in the past 6 months
• Use of risperidone
|- mec approval received||yes|
|- multicenter trial||yes|
|- Type||Single arm|
|- planned startdate ||1-jan-2015|
|- planned closingdate||1-feb-2016|
|- Target number of participants||200|
|- Interventions||discontinuation of long-term used antipsychotics for behavioural symptoms whereby dosereduction will take place every two weeks with appr. 12.5 % of baseline dosage in a time schedule of 14 weeks|
|- Primary outcome||Behaviour:|
The five subscales of the Aberrant Behavior Checklist (ABC) i.e., irritability, hyperactivity, lethargy, stereotypic behavior and inappropriate speech, and the Clinical Global Impression scale Improvement (CGI-I).
item 1 through 9 of the Abnormal Involuntary Movement Scale (AIMS), the Barnes akathisia objective symptoms, subjective symptoms and burden scale scale, and items 20, 21, 22, and 31 of the Unified Parkinson Scale (UPDRS).
Autonomic symptoms will be measured by the Scale for Outcomes in Parkinson‘s disease-Autonomic Symptoms (SCOPA-AUT).
Characteristics of caregivers:
Translated and validated versions of the Challenging Behavior Self Efficacy Scale and the Emotional reactions to challenging behavior scale
|- Secondary outcome||Quality of life:
The subscales “emotional-wellbeing” and “physical-wellbeing” of the quality of life (QUOL) related personal outcomes scale (POS), |
|- Timepoints||Data collection will take place at baseline and at 4, 8, 12, and 16 weeks after the first dose reduction. Follow-up data collection is at 6, 12, and 26 weeks after the scheduled time point of complete discontinuation. |
|- Trial web site|
|- status||stopped: trial finished|
|- CONTACT FOR PUBLIC QUERIES|| Gerda Kuijper de|
|- CONTACT for SCIENTIFIC QUERIES|| Gerda Kuijper de|
|- Sponsor/Initiator ||University Medical Center Groningen (UMCG)|
(Source(s) of Monetary or Material Support)
|- Brief summary||Rationale: People with intellectual disability (ID) frequently use long-term antipsychotic drugs for challenging behaviors, although the efficacy in this indication has not been proven. Moreover, antipsychotics may cause harmful side effects, which may negatively influence quality of life. Especially neurological side-effects may be serious and sometimes life threatening or irreversible. In order to prevent iatrogenic damage caused by unnecessary antipsychotic drug use discontinuation should be considered. |
In daily practice successful discontinuation of antipsychotics may be hampered by neurological withdrawal symptoms, which may remain clinically undiagnosed. Withdrawal symptoms may cause distress and an increase in behavioural symptoms, thus likely leading to higher dosage and ongoing use of the antipsychotic drug. Also, staff- related factors like knowledge and cognitions of psychotropic drug use and attitudes towards challenging behaviours of their clients may influence a successful discontinuation trajectory.
Objectives: To investigate whether the occurrence and severity of neurological withdrawal symptoms during the discontinuation trajectory is associated with achievement of complete discontinuation. To investigate staff-related factors which may be associated with successful discontinuation of antipsychotics used for challenging behaviours in people with ID.
Secondary objectives: To study the effect of discontinuation on health related quality of life. To study whether there is an association of severity of neurological side effects with health related quality of life
Study design: Prospective study
Study population: People with intellectual disability aged six years and over, who use antipsychotic drugs for challenging behaviours for more than one year and who are presented a treatment proposal of an attempt to scheduled discontinuation by their physicians, as part of their regular treatment.
Intervention: A series of eight brief medical exams during the discontinuation trajectory, in which antipsychotics will be tapered off by lowering the dose every 2 weeks with 12.5% of baseline dosage.
Main study parameters: Study parameters are scores of extrapyramidal symptoms, scores of behavioral measurements, scores of questionnaires of staff-related factors and scores of questionnaires of health related quality of life.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The proposed treatment is part of regular medical practice. Also, the medical assessments of physical symptoms are part of regular medical medication controls whereby the burden is minimal. It is obvious that study of medication discontinuation in patients with intellectual disability can only be performed in intellectually disabled participants.
|- Main changes (audit trail)|
|- RECORD||4-nov-2015 - 22-okt-2017|